Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05126147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hydroxychloroquine in Mild Graves' Orbitopathy

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 25, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Sep 30, 2025 Completion date: Dec 31, 2024 to Dec 31, 2026v4 Show 1 more changeShow less
    • Completion date: Dec 31, 2024 to Dec 31, 2026
  2. Primary completion date: Mar 21, 2023 to Dec 31, 2024 Site contacts updated at 1 of 2 sitesv3 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 1, 2021 to Mar 21, 2022 · Enrollment target: 104 to 108 · Study sites: 1 to 2 · 5 morev2 Show 8 more changesShow less
    • Start date changed from estimate of Dec 1, 2021 to Mar 21, 2022
    • Enrollment target: 104 to 108
    • Study sites: 1 to 2
    • Primary completion date: Dec 1, 2023 to Mar 21, 2023
    • Completion date: Dec 1, 2024 to Dec 31, 2024
    • Eligibility criteria shortened, about 18 words
    • Study description shortened, about 34 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).
Trial Details
NCT Number NCT05126147
Lead Sponsor National Taiwan University Hospital
Conditions Graves Ophthalmopathy
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov